BAM
PACB icon

Belpointe Asset Management’s Pacific Biosciences PACB Stock Holding History

Belpointe Asset Management’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,000
Closed -$11.6K – 2487
2023
Q1 		$11.6K Hold
1,000
– – ﹤0.01% 2636
2022
Q4 		$8.18K Buy
+1,000
New +$8.62K ﹤0.01% 2716
2022
Q1 		– Sell
-6,500
Closed -$133K – 1284
2021
Q4 		$133K Buy
6,500
+866
+15% +$20.9K 0.01% 1075
2021
Q3 		$144K Buy
+5,634
New +$167K 0.01% 998

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Belpointe Asset Management's PACB Position: Q2 2023 in Review

Belpointe Asset Management sold out of Pacific Biosciences (PACB) in Q2 2023, closing a stake of 1,000 shares — an estimated $11.6K sold.

Belpointe Asset Management first reported a position in PACB in Q3 2021 and held it in 4 quarters. The position peaked at $144K in Q3 2021. 272 funds tracked by Wall St. Rank hold PACB as of Q2 2023.

  • Belpointe Asset Management reported no remaining Pacific Biosciences position as of Q2 2023 after selling out during the quarter.
  • Belpointe Asset Management sold 1,000 Pacific Biosciences shares in Q2 2023, an estimated $11.6K.
  • Belpointe Asset Management first reported a position in Pacific Biosciences in Q3 2021 and held it in 4 quarters.
  • Belpointe Asset Management's Pacific Biosciences position peaked at $144K in Q3 2021.
  • 272 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2023.

Based on Belpointe Asset Management's 13F filing for Q2 2023, filed 15 Aug 2023.